Navigation Links
In-depth investigation on the capacity of 4-HPR to induce death of tumor cells
Date:9/7/2010

This release is available in Spanish.

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25 % of cases and which can lead to death. The development of 4-HPR, a synthetic derivative of RA, has meant a considerable advance due to its greater efficacy compared to its predecessor. It is able to induce the death of tumour cells as the method for reducing their proliferation, in a precise manner and without serious damage to surrounding tissue. Moreover, it halts the referred-to retinoic acid syndrome and even functions with cells that resist RA. In vitro studies corroborate its effectiveness as a chemopreventive agent and also as a chemotherapeutic agent, both with leukaemias and with ovary, breast or brain tumour cells.

Biologist Ms Aintzane Apraiz studied the 4-HPR in depth, focusing on the causes that, according to previous research, give rise to this ability to induce cell death. To this end, she applied this synthetic derivative to acute lymphoblastic leukaemia T cells (LLA-T). Her PhD thesis, defended at the University of the Basque Country (UPV/EHU), is entitled Role of sphingolipids and oxidative stress in the antineoplasic activity of 4-HPR: study in a leucemia model.

Not such a direct relation

Amongst the various processes that can induce cell death, in the case of 4-HPR, apoptosis is outstanding; a precise mechanism and without inflammatory processes or serious damage to surrounding tissue. According to Ms Apraiz, previous research on LLA-T undertaken by the team of which she is a member, showed that 4-HPR induced a massive accumulation of ceramides (lipids of the cell membrane) and of reactive oxygen species (ROS), both of which can cause cell death. However, the PhD thesis shows that the cause-effect relation is not so direct.

To start with, thanks to new technological advances, Ms Apraiz has been able to show that it is not the ceramides that are accumulated due to the 4-HPR effect, but their precursors dihydroceramides, these latter thought to date to be biologically inactive. Moreover, the thesis concludes that the accumulation of these dihydroceramides does not cause cell death, as it occurs in cells both resistant and sensitive to 4-HPR. If such accumulation was a key to cell death, it would not occur in the same way in resistant cells.

As regards the relation between the accumulation of ROS and cell death, the PhD thesis concludes that there is a direct connection in this case, but this in itself does not explain the whole process. In fact, Ms Apraiz observed that, even using antioxidants such as NDGA in order to neutralise the accumulation of ROS, the 4-HPR continued to be able to induce cell death.

Compatible with alternative therapies

Ms Apraiz also showed that, in the case of failure of treatment with 4-HPR, the possible effectiveness of alternative therapies is not affected. That is, the researcher observed that, unlike what happens with other treatments, the LLA-T cells that become resistant to 4-HPR continue to be sensitive to other compounds, and so alternative therapies based on these latter compounds may well continue to be effective even though the 4-HPR has failed.


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert  

Related medicine news :

1. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
2. New investigation supports correlation between XMRV and prostate cancer
3. Pivotal data for the investigational treatment PSD502 for primary premature ejaculation
4. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
5. Dementia Rates Escalate as Brain Capacity Diminishes with Age
6. Private Sector, President's Malaria Initiative Join Forces to Strengthen Angolas Capacity to Control Mosquitoes
7. Sinovac Completes Acquisition Aimed at Expanding Production Capacity
8. A midday nap markedly boosts the brains learning capacity
9. More than one-quarter of elderly patients lack decision-making capacity at death
10. Hispanics live in areas with limited capacity for colorectal cancer screening
11. New VKernel AppVIEW 1.0 for Monitoring and Identification of Capacity Bottlenecks in Critical Application VMs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
In-depth investigation on the capacity of 4-HPR to induce death of tumor cells
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: